Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Towards elucidating the radiochemistry of astatine - Behavior in chloroform

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio-Crosslinking

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Extraction of 211At from nitric acid solutions into various organic solvents for use as an α-source for radiation chemistry studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Elin Cederkrantz
  • Håkan Andersson
  • Peter Bernhardt
  • Tom Bäck
  • Ragnar Hultborn
  • Lars Jacobsson
  • Holger Jensen
  • Sture Lindegren
  • Michael Ljungberg
  • Tobias Magnander
  • Stig Palm
  • Per Albertsson
View graph of relations

PURPOSE: Ovarian cancer is often diagnosed at an advanced stage with dissemination in the peritoneal cavity. Most patients achieve clinical remission after surgery and chemotherapy, but approximately 70% eventually experience recurrence, usually in the peritoneal cavity. To prevent recurrence, intraperitoneal (i.p.) targeted α therapy has been proposed as an adjuvant treatment for minimal residual disease after successful primary treatment. In the present study, we calculated absorbed and relative biological effect (RBE)-weighted (equivalent) doses in relevant normal tissues and estimated the effective dose associated with i.p. administration of (211)At-MX35 F(ab')2.

METHODS AND MATERIALS: Patients in clinical remission after salvage chemotherapy for peritoneal recurrence of ovarian cancer underwent i.p. infusion of (211)At-MX35 F(ab')2. Potassium perchlorate was given to block unwanted accumulation of (211)At in thyroid and other NIS-containing tissues. Mean absorbed doses to normal tissues were calculated from clinical data, including blood and i.p. fluid samples, urine, γ-camera images, and single-photon emission computed tomography/computed tomography images. Extrapolation of preclinical biodistribution data combined with clinical blood activity data allowed us to estimate absorbed doses in additional tissues. The equivalent dose was calculated using an RBE of 5 and the effective dose using the recommended weight factor of 20. All doses were normalized to the initial activity concentration of the infused therapy solution.

RESULTS: The urinary bladder, thyroid, and kidneys (1.9, 1.8, and 1.7 mGy per MBq/L) received the 3 highest estimated absorbed doses. When the tissue-weighting factors were applied, the largest contributors to the effective dose were the lungs, stomach, and urinary bladder. Using 100 MBq/L, organ equivalent doses were less than 10% of the estimated tolerance dose.

CONCLUSION: Intraperitoneal (211)At-MX35 F(ab')2 treatment is potentially a well-tolerated therapy for locally confined microscopic ovarian cancer. Absorbed doses to normal organs are low, but because the effective dose potentially corresponds to a risk of treatment-induced carcinogenesis, optimization may still be valuable.

Original languageEnglish
JournalInternational Journal of Radiation: Oncology - Biology - Physics
Issue number3
Pages (from-to)569-76
Number of pages8
Publication statusPublished - 1 Nov 2015

    Research areas

  • Alpha Particles, Antibodies, Monoclonal, Astatine, Electrons, Female, Humans, Immunoconjugates, Immunoglobulin Fab Fragments, Kidney, Lung, Neoplasm Recurrence, Local, Neoplasm, Residual, Ovarian Neoplasms, Peritoneal Neoplasms, Proton Therapy, Radioimmunotherapy, Radiotherapy Dosage, Relative Biological Effectiveness, Risk Assessment, Stomach, Thyroid Gland, Tissue Distribution, Tomography, Emission-Computed, Single-Photon, Urinary Bladder

ID: 46266642